StockMarketWire.com - Diagnostics company Genedrive said it had completed the assay design of its COVID-19 testing and was now generating 'very promising' analytical data aligned to market requirements.

The company's SARS-CoV-2 POC Kit was being designed to detect the Covid-19 virus in saliva without the need to extract viral RNA.

'This expanded the potential use areas of the product and importantly, allows for rapid testing to be performed while a patient was present,' the company said.





At 8:32am: [LON:GDR] Genedrive Plc share price was -4.5p at 108.5p



Story provided by StockMarketWire.com